350 related articles for article (PubMed ID: 25851942)
21. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.
Yoshida K; Kodera Y; Kochi M; Ichikawa W; Kakeji Y; Sano T; Nagao N; Takahashi M; Takagane A; Watanabe T; Kaji M; Okitsu H; Nomura T; Matsui T; Yoshikawa T; Matsuyama J; Yamada M; Ito S; Takeuchi M; Fujii M
J Clin Oncol; 2019 May; 37(15):1296-1304. PubMed ID: 30925125
[TBL] [Abstract][Full Text] [Related]
22. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
[TBL] [Abstract][Full Text] [Related]
23. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
25. [Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
Zhou AP; Li YS; Yang L; Song Y; Sun YK; Zhang W; Cui CX; Chi Y; Yuan XH; Lü N; Wang JW
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1677-80. PubMed ID: 22944157
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Kunisaki C; Takahashi M; Makino H; Oshima T; Fujii S; Takagawa R; Kimura J; Kosaka T; Ono HA; Akiyama H; Kameda K; Kito F; Morita S; Endo I
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1363-8. PubMed ID: 20803016
[TBL] [Abstract][Full Text] [Related]
27. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Park SR; Kim HK; Kim CG; Choi IJ; Lee JS; Lee JH; Ryu KW; Kim YW; Bae JM; Kim NK
Br J Cancer; 2008 Apr; 98(8):1305-11. PubMed ID: 18362939
[TBL] [Abstract][Full Text] [Related]
29. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.
Fushida S; Nashimoto A; Fukushima N; Kawachi Y; Fujimura T; Kuwabara S; Musha N;
Jpn J Clin Oncol; 2012 Feb; 42(2):131-3. PubMed ID: 22167664
[TBL] [Abstract][Full Text] [Related]
33. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
Aoyama T; Nishikawa K; Fujitani K; Tanabe K; Ito S; Matsui T; Miki A; Nemoto H; Sakamaki K; Fukunaga T; Kimura Y; Hirabayashi N; Yoshikawa T
Ann Oncol; 2017 Aug; 28(8):1876-1881. PubMed ID: 28486692
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
38. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
39. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Makino H; Takagawa R; Kimura J; Ono H; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2014 Feb; 73(2):281-5. PubMed ID: 24253176
[TBL] [Abstract][Full Text] [Related]
40. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
Shigeyasu K; Kagawa S; Uno F; Nishizaki M; Kishimoto H; Gochi A; Kimura T; Takahata T; Nonaka Y; Ninomiya M; Fujiwara T
Cancer Chemother Pharmacol; 2013 Apr; 71(4):937-43. PubMed ID: 23355040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]